Astria Therapeutics Reports Expanded Net Loss in Q1 2025

Summary

Astria Therapeutics reports a net loss of $33.7 million for Q1 2025, up from $19.9 million in Q1 2024, with a per-share net loss of $0.58. Cash reserves decreased to $295.1 million, expected to support operations until mid-2027. The company is recruiting patients for the Phase 3 Alpha-Orbit trial of Navenibart, with results anticipated in mid-2025 and Q3 2025. Astria will also participate in a June 2025 investor conference. Reuters

Impact Analysis

1. Business Overview Analysis